Results: SVR Genotype Non-1

SVR (%)

24 weeks

48 weeks

78%

73%

77%

n=106

n=162

n=111

n=165

PEGASYSÆRBV 800

PEGASYSÆRBV 1000/1200

PEGASYSÆRBV 800

PEGASYSÆRBV 1000/1200

Previous slide Next slide Back to first slide View graphic version

Notes:

No efficacy benefit seen in Non-1 when increase treatment duration from 24 to 48 wks and/or when increase RBV from the lower, 800mg dose to the standard dose.

Due to time will not show split for viral titre but will say no difference